A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs HMR-59 (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors Hemera Biosciences
- 18 Dec 2017 Planned End Date changed from 31 Oct 2019 to 6 Dec 2019.
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 15 May 2017 New trial record